US and Europe Injectable Drug Delivery Market Demand & Opportunities 2031
US and Europe Injectable Drug Delivery Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Devices Type (Conventional Drug Delivery Devices and Advanced Drug Delivery Devices), Formulation (Conventional Drug Delivery, Novel Drug Delivery, and Long Acting Injectable Formulations), Formulation Packaging (Ready-to-use ampoules, Vials, Cartridges, and Bottles), Therapeutic Application (Diabetes, Oncology, Autoimmune Disorders, Cardiovascular Diseases, Infectious Diseases, Pain Management, and Other Therapeutic Applications), Usability (Disposable Injectors and Reusable Injectors), Route Of Administration (Sub-cutaneous, Intramuscular, Intravenous and Other Route of Administrations), End User (Pharmaceutical and Biopharma Companies and CMOs and CDMOs), and Geography
Historic Data: 2021-2023 | Base Year: 2024 | Forecast Period: 2025-2031- Report Code : TIPRE00042033
- Category : Life Sciences
- No. of Pages : 210
- Available Report Formats :
The US and Europe injectable drug delivery market size is projected to reach US$ 46.74 billion by 2031 from US$ 27.17 billion in 2024. The market is expected to register a CAGR of 8.2% from 2025 to 2031.
US and Europe Injectable Drug Delivery Market Analysis
The rising prevalence of diabetes and demand for self-administered biologics, advancements in oncology and biologics requiring precision delivery, and expansion in autoimmune and cardiovascular disease management are key factors driving market growth. Additionally, rising approvals of biologics and novel drugs, growth of rare-disease and specialty therapies, and regulatory support and innovation momentum are expected to create ample opportunities for the US and Europe injectable drug delivery market in the coming years.
US and Europe Injectable Drug Delivery Market Overview
The US market is supported by advanced regulatory frameworks, favorable reimbursement policies, and widespread adoption of innovative delivery technologies such as autoinjectors, prefilled syringes, and wearable injectors. Europe is the second largest contributor due to supportive healthcare systems, increasing elderly populations, and the rising usage of biosimilars and patient-centric therapies. The market in Europe is more focused on safety and quality, as well as an increase in home-based care and regulatory support for advanced delivery systems. Innovation in technology and a rise in the number of people receiving outpatient care are the main factors driving the growth of the market.
Customize This Report To Suit Your Requirement
Get FREE CUSTOMIZATIONUS and Europe Injectable Drug Delivery Market: Strategic Insights
-
Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
US and Europe Injectable Drug Delivery Market Drivers and Opportunities
Market Drivers:
- Rising Prevalence of Diabetes and Demand for Self-Administered Biologics : The rise in diabetes cases in the US and Europe is leading to a higher demand for self-administered injectable biologics, which is facilitated by innovations in autoinjectors, regulatory approvals, and increased public research funding.
- Advancements in Oncology and Biologics Requiring Precision Delivery: The increase in cancer cases and use of biologic-based oncology therapies is resulting in a need for precision injectable delivery systems, which is leading to oncology drug approvals and innovations that improve safety, dosing accuracy, and targeted treatment.
- Expansion in Autoimmune and Cardiovascular Disease Management: The surge in autoimmune and cardiovascular diseases has led to a rise in the use of injectable biologics and anticoagulants, which is supported by the introduction of new autoinjectors, prefilled syringes, and the increasing government investment in chronic disease management.
Market Opportunities:
- Rising Approvals of Biologics and Novel Drugs: The EMA and FDA are approving more biologics and novel drugs; thus, the demand for high-quality injectable delivery systems is increasing, such as vials, prefilled syringes, and autoinjectors.
- Growth of Rare-Disease and Specialty Therapies: Increasing approvals of rare-disease, oncology, and biologic-SOL-generic living-generic therapies are leading to the need for advanced injectable delivery solutions, specialty packaging, and cold-chain compatible systems.
- Regulatory Support and Innovation Momentum: Strong support of pharmaceutical innovation by EMA and FDA is resulting in biologic drug pipelines being faster, which is creating a continuous demand for scalable, compliant injectable delivery infrastructure and advanced device technologies.
US and Europe Injectable Drug Delivery Market Report Segmentation Analysis
The US and Europe injectable drug delivery market is divided into different segments to give a clearer view of how it works, its growth potential, and the latest trends. Below is the standard segmentation approach used in industry reports:
By Device Type:
- Conventional Drug Delivery Devices: Conventional injectable devices are the main instruments employed in the US and Europe, which is attributed to their low cost, clinicians being familiar with them, the support of the reimbursement system, and well-established supplier networks. As a result, prefilled syringes are preferred in chronic and vaccination applications.
- Advanced Drug Delivery Devices: Advanced injectable devices are likely to emerge as a major trend in the US and Europe over the next several years. This change is powered by biologics, self-administration at home, regulations that support the process, reimbursement that is getting more and more widely available, and innovation in connected, patient-centric delivery technologies.
By Formulation:
- Conventional Drug Delivery
- Novel Drug Delivery
- Long-Acting Injectable Formulations
By Formulation Packaging (ready-to-use):
- Ampoules
- Vials
- Cartridges
- Bottles
Therapeutic Application:
- Diabetes
- Oncology
- Autoimmune Disorders
- Cardiovascular Diseases
- Infectious Diseases
- Pain Management
- Other Therapeutic Applications
Usability:
- Disposable Injectors
- Re-usable Injectors
Route Of Administration:
- Sub-cutaneous
- Intramuscular
- Intravenous
- Other Routes of Administration
End User:
- Pharmaceutical and Biopharma Companies
- CMOs and CDMOs
By Geography:
- US
- Europe
US and Europe Injectable Drug Delivery Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 27.17 Billion |
| Market Size by 2031 | US$ 46.74 Billion |
| CAGR (2025 - 2031) | 8.2% |
| Historical Data | 2021-2023 |
| Forecast period | 2025-2031 |
| Segments Covered |
By Devices Type
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
US and Europe Injectable Drug Delivery Market Players Density: Understanding Its Impact on Business Dynamics
The US and Europe Injectable Drug Delivery Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
US and Europe Injectable Drug Delivery Market Share Analysis by Geography
The US and Europe are expected to grow the fastest in the next few years. These markets present opportunities for injectable drug delivery providers.
The US and Europe injectable drug delivery market grows differently in each region. The contract development, manufacturing organizations (CDMOs), and strategic supplier networks that prioritize precision, scalability, and regulatory alignment are the major driving factors. Below is a summary of market share and trends by region:
1. US and Europe
- Market Share: The US holds a significant portion of the market
- Key Drivers: Rising prevalence of chronic diseases and expanding biologics pipelines are driving demand for safe, cost-effective, and patient-friendly injectable drug delivery systems.
- Trends: Emergence of wearable, connected, and smart injectable devices
Injectable Drug Delivery Market Players Density: Understanding Its Impact on Business Dynamics
High Market Density and Competition
Competition is intense due to the presence of established players such as Becton, Dickinson and Company (BD), West Pharmaceutical Services, Inc., Gerresheimer AG, Ypsomed Holding AG, and SHL Medical AG. Regional and niche players add to the competitive landscape across different regions.
This high level of competition urges companies to stand out by offering:
- Advanced Products
- Value-added services such as customization and sustainable solutions
- Competitive pricing models
- Regulatory compliance
Opportunities and Strategic Moves
- Biologics and sterile injectables for chronic conditions such as diabetes, cancer, and autoimmune diseases, accompanied by self-administration devices, are the main contributors to the surge of home-care adoption.
- Wearables, pen-injectors, and AI-optimized formulations for sustained release are strategies aimed at dosing frequency reduction and compliance enhancement.
- The expansion is happening in hospitals and retail pharmacies, as well as through CDMO partnerships for scalable production. INCOG's US$ 200 million Indiana expansion for 480 million autoinjector units; PCI's US$ 365 million in US/EU for drug-device combos; Selkirk's ClinFAST for rapid clinical fill-finish.
Other companies analyzed during the course of research:
- Vetter Pharma-Fertigung GmbH & Co. KG
- SHL Medical AG
- Owen Mumford Ltd.
- Haselmeier GmbH
- Elcam Medical
- Johnson & Johnson Services, Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Novo Nordisk A/S
- Sanofi S.A.
- AstraZeneca Plc
- Novartis AG
- AbbVie Inc.
- Biocon
- Antares Pharma Inc.
- Catalent, Inc.
- Medtronic plc
- Insulet Corporation
- Credence MedSystems Inc.
- Teva Pharmaceutical Industries Ltd.
Injectable Drug Delivery Market News and Recent Developments
- West Synchrony Prefillable Syringe System Launches at CPHI - In October 2025, West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced the launch of its West Synchrony Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, Germany. This innovative system marks a significant shift in drug delivery solutions by offering a fully verified platform from a single supplier that will be commercially available in January 2026.
- SCHOTT Pharma Launches Next Gen Polymer Syringe System - In January 2025, SCHOTT Pharma, a provider of drug containment and delivery solutions, launched the next generation of SCHOTT TOPPAC infuse polymer syringes. Developed with SCHOTT Pharma’s Alliance to Zero partners, Schreiner MediPharm and Korber Pharma, the system consists of a new cap, a functional label, and carton packaging. This solution aims to address challenges hospitals face, including high levels of medication waste, inefficient manual processes, and storage constraints.
Injectable Drug Delivery Market Report Coverage and Deliverables
The " Injectable Drug Delivery Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
- US and Europe injectable drug delivery market size and forecast at the regional and country levels for all the key market segments covered under the scope
- US and Europe injectable drug delivery market trends, as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- US and Europe injectable drug delivery market analysis covering key trends, regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the US and Europe injectable drug delivery market
- Detailed company profiles
Frequently Asked Questions
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Recent Reports
Testimonials
The Insight Partners' SCADA System Market report is comprehensive, with valuable insights on current trends and future forecasts. The team was highly professional, responsive, and supportive throughout. We are very satisfied and highly recommend their services.
RAN KEDEM Partner, Reali Technologies LTDs
I requested a report on a very specific software market and the team produced the report in a few days. The information was very relevant and well presented. I then requested some changes and additions to the report. The team was again very responsive and I got the final report in less than a week.
JEAN-HERVE JENN Chairman, Future Analytica
We worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.
PIYUSH NAGPAL Sr. Vice President, High Beam Global
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
YUKIHIKO ADACHI CEO, Deep Blue, LLC.
This is the first time I have purchased a market report from The Insight Partners.While I was unsure at first, I visited their web site and felt more comfortable to take the risk and purchase a market report.I am completely satisfied with the quality of the report and customer service. I had several questions and comments with the initial report, but after a couple of dialogs over email with their analyst I believe I have a report that I can use as input to our strategic planning process.Thank you so much for taking the extra time and making this a positive experience.I will definitely recommend your service to others and you will be my first call when we need further market data.
JOHN SUZUKI President and Chief Executive Officer, Board Director, BK Technologies
I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Identifying Emerging Markets
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Boosting Operational Efficiency
- Strategic Planning
- Investment Justification
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Get Free Sample For